{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/paritaprevir",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(in fixed-dose combination with dasabuvir)</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (in fixed-dose combination with dasabuvir)   decreases   the anticoagulant effect of   acenocoumarol .  Manufacturer advises monitor INR and adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   aliskiren .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-substanceQualifier\">(boosted with ritonavir)</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or give unboosted</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   (boosted with ritonavir)   markedly   increases   the exposure to   paritaprevir .  Manufacturer advises avoid or give unboosted .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(in fixed-dose combination)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (in fixed-dose combination)   is predicted to   increase   the risk of rhabdomyolysis when given with   atorvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"combined hormonal contraceptives\" outputclass=\"int-drug\">Combined hormonal contraceptives</ph> <ph outputclass=\"int-substanceQualifier\">(containing ethinylestradiol)</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of increased ALT concentrations when given with</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Combined hormonal contraceptives   (containing ethinylestradiol)   are predicted to   increase   the risk of increased ALT concentrations when given with   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Combined hormonal contraceptives</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">dabigatran</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   dabigatran .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-substanceQualifier\">(boosted with ritonavir)</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or give unboosted</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   (boosted with ritonavir)   slightly   decreases   the exposure to   paritaprevir .  Manufacturer advises avoid or give unboosted .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust <ph otherprops=\"digoxin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/digoxin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP752\">digoxin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   increases   the exposure to   digoxin .  Manufacturer advises monitor and adjust  digoxin  dose .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">edoxaban</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   edoxaban .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises monitor side effects .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etravirine\" outputclass=\"int-drug\">Etravirine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etravirine   is predicted to   decrease   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etravirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvastatin\" outputclass=\"int-drug\">fluvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   fluvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-substanceQualifier\">(boosted with ritonavir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   (boosted with ritonavir)   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   furosemide .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">idelalisib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   is predicted to   increase   the exposure to   idelalisib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"levothyroxine\" outputclass=\"int-drug\">levothyroxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   levothyroxine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levothyroxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"loperamide\" outputclass=\"int-drug\">loperamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   loperamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loperamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-substanceQualifier\">(boosted with ritonavir)</ph> <ph outputclass=\"int-magnitude\">moderately to markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   (boosted with ritonavir)   moderately to markedly   increases   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   paclitaxel .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> and <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">posaconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   paritaprevir   (with ritonavir and ombitasvir)  and  paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   posaconazole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pravastatin\" outputclass=\"int-drug\">pravastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"pravastatin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/pravastatin-sodium.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1642\">pravastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   increases   the exposure to   pravastatin .  Manufacturer advises adjust  pravastatin  dose .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pravastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-magnitude\">slightly to moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   slightly to moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(in fixed-dose combination)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Saquinavir   is predicted to   increase   the exposure to   paritaprevir   (in fixed-dose combination) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(in fixed-dose combination)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (in fixed-dose combination)   is predicted to   increase   the risk of rhabdomyolysis when given with   simvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's Wort   is predicted to   decrease   the exposure to   paritaprevir   (with ritonavir and ombitasvir) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-substanceQualifier\">(boosted with ritonavir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   (boosted with ritonavir)   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(with ritonavir and ombitasvir)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (with ritonavir and ombitasvir)   is predicted to   increase   the exposure to   topotecan .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">paritaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   paritaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/paritaprevir#bnf_i1557280750625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paritaprevir\" outputclass=\"int-heading-drug\">Paritaprevir</ph> <ph outputclass=\"int-substanceQualifier\">(in fixed-dose combination)</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paritaprevir   (in fixed-dose combination)   decreases   the anticoagulant effect of   warfarin .  Manufacturer advises monitor INR and adjust dose .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Paritaprevir  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/paritaprevir.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Paritaprevir </title>"
			},
			"rdfs:label": "paritaprevir"
		}
	]
}